Filament Health Achieves Milestone with First Botanical Psilocybin Export to Australia

NEW YORK – Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS), a trailblazer in the realm of natural psychedelic drug development, announced a significant milestone in its global expansion with the successful export of PEX010, its botanical psilocybin drug candidate, to Perth, Western Australia. This shipment, received by Reset Mind Sciences Ltd., a subsidiary of Little Green Pharma, marks a historic first in the Australian psilocybin industry.

Lisa Ranken, Chief Operating Officer at Filament Health, highlighted the achievement as a testament to the company’s robust regulatory capabilities. She noted, “This is the first legal shipment of a botanical psilocybin drug candidate to arrive in Australia, and we are pleased to see a natural option being explored by Australian researchers.”

Dr. Leon Warne, Chief Operating Officer of Reset, emphasized the significance of this naturally sourced psilocybin shipment for both Reset and the burgeoning Australian psilocybin industry. Since July 1, 2023, authorized psychiatrists in Australia have been permitted to prescribe psilocybin for treatment-resistant depression, marking a progressive shift in the country’s approach to mental health treatment.

Reset is currently advancing its application for a GMP license to manufacture psilocybin products derived from botanically sourced psilocybin. This development comes as the Australian Therapeutic Goods Administration (TGA) prepares to publish a Therapeutic Goods Order governing the production of psilocybin in the country.

About Filament Health: A clinical-stage entity, Filament Health is dedicated to developing natural, standardized, and safe psychedelic medicines. The company’s mission is to make these naturally-derived psychedelic medicines accessible to those in need. Filament’s proprietary platform encompasses the discovery, development, and delivery of natural psychedelic medicines, positioning it as a pioneer in the field with the first-ever natural psychedelic drug candidates.

This export represents a significant step for Filament Health in expanding the reach of its botanical psilocybin drug candidate, potentially opening new pathways for mental health treatment and research in Australia. The collaboration between Filament Health and Australian entities like Reset Mind Sciences could signal a new era in the global acceptance and application of natural psychedelic substances for therapeutic purposes.